AMPHASTAR PHARMACEUTICALS INC financial statements, including revenue, expenses, profit, and loss

The total revenue of 29A for the last quarter is 159.25 M EUR, and it's 1.31% lower compared to the previous quarter. The net income of Q1 24 is 40.02 M EUR.